Systemic tumour necrosis factor (TNF) treatment in psoriasis: clinical data from a total of 14 patients in an open trial
- 1 January 1994
- journal article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 5 (3) , 133-137
- https://doi.org/10.3109/09546639409084553
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Effects of recombinant tumor necrosis factor (rHuTNFα)on human neutrophils and monocytes: In vitro, ex vivo and in vivoEuropean Journal of Haematology, 2009
- Surprisingly high levels of anaphylatoxin C5a des Arg are extractable from psoriatic scalesArchives of Dermatological Research, 1993
- Therapeutic use of cytokines in dermatologyJournal of the American Academy of Dermatology, 1991
- Response to tumor necrosis factor in two cases of psoriasisJournal of the American Academy of Dermatology, 1991
- Tumor necrosis factorJournal of the American Academy of Dermatology, 1991
- Normal human epidermal keratinocyte-derived neutrophil chemotactic factor.The Tohoku Journal of Experimental Medicine, 1990
- Tumor Necrosis Factor and Disease Severity in Children with Falciparum MalariaNew England Journal of Medicine, 1989
- Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factorJournal of the American Academy of Dermatology, 1989
- Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes.Journal of Clinical Investigation, 1989
- Recombinant human tumor necrosis factor α lacks chemotactic activity for human peripheral blood neutrophils and monocytesBiochemical and Biophysical Research Communications, 1988